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Background: Multiple Sclerosis (MS) is an autoimmune demyelinating disease that occurs more frequently in
women than in men. Multiple Sclerosis Associated Retrovirus (MSRV) is a member of HERV-W, a multicopy human
endogenous retroviral family repeatedly implicated in MS pathogenesis. MSRV envelope protein is elevated in the
serum of MS patients and induces inflammation and demyelination but, in spite of this pathogenic potential, its
exact genomic origin and mechanism of generation are unknown. A possible link between the HERV-W copy on
chromosome Xq22.3, that contains an almost complete open reading frame, and the gender differential prevalence
in MS has been suggested.
Results: MSRV transcription levels were higher in MS patients than in controls (U-Mann–Whitney; p = 0.004). Also,
they were associated with the clinical forms (Spearman; p = 0.0003) and with the Multiple Sclerosis Severity Score
(MSSS) (Spearman; p = 0.016). By mapping a 3 kb region in Xq22.3, including the HERV-W locus, we identified three
polymorphisms: rs6622139 (T/C), rs6622140 (G/A) and rs1290413 (G/A). After genotyping 3127 individuals (1669
patients and 1458 controls) from two different Spanish cohorts, we found that in women rs6622139 T/C was
associated with MS susceptibility: [χ2; p = 0.004; OR (95% CI) = 0.50 (0.31-0.81)] and severity, since CC women
presented lower MSSS scores than CT (U-Mann–Whitney; p = 0.039) or TT patients (U-Mann–Whitney; p = 0.031).
Concordantly with the susceptibility conferred in women, rs6622139*T was associated with higher MSRV expression
(U-Mann–Whitney; p = 0.003).
Conclusions: Our present work supports the hypothesis of a direct involvement of HERV-W/MSRV in MS
pathogenesis, identifying a genetic marker on chromosome X that could be one of the causes underlying the
gender differences in MS.
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Human endogenous retroviruses (HERVs) are believed
to be remnants of ancient exogenous infections. They
entered the germ line during primate evolution and as
retroviruses were able to replicate and retrotranspose,
increasing their copy number and spreading all over the
genome. Indeed, approximately an 8% of the genome
has a retroviral origin [1]. During evolution, most of the
HERV proviruses have undergone extensive mutations
and are unable to replicate. Nowadays, they reside in the
genome of all human cells and are transmitted in Men-
delian fashion.
Retroviruses typically consist of an internal region
containing gag, pro, pol, and env genes, flanked by two
long terminal repeats (LTR). Some HERVs have retained
open reading frames (ORFs) putatively encoding func-
tional proteins. These proteins can display a physio-
logical role, as Syncytin-1 which is involved in the
formation of the syncytiotrophoblast during pregnancy
[2]; but as viral products, they might show antigenic
properties involving the immune system. Indeed, HERVs
have been associated with several pathologies as cancer
and autoimmune diseases. HERVs RNAs, proteins or vi-
rions have been found in different tumor tissues [3-7], in
schizophrenia [8-10], rheumatoid arthritis [11] and espe-
cially in multiple sclerosis (MS) [12,13].
Mainly two HERV families have been related to MS:
HERV-W and HERV-H; and among them, the member
most intensively studied is MSRV, a HERV-W-related
retroelement [14].
Depending on the cohort studied, the percentage of
MS serum or plasma samples positive to MSRV ranges
from 50% [15] to 100% [16]. Enhanced expression of
MSRV was also detected in MS plaques in independent
post-mortem brain studies [17-19] and increased MSRV
copy number in MS blood DNA was associated with a
poorer MS prognosis [20,21]. Besides, interferon-beta
reduces MSRV load in MS patients with a good clinical
response to the treatment [22], suggesting that it could
be a biomarker to monitor disease progression and
therapy outcome.
MSRV might be exerting its role in MS pathogenesis
through the activation of innate immunity and subsequent
release of pro-inflammatory cytokines [23] through Toll-
like receptor (TLR-4) [24]. It acts as a superantigen produ-
cing polyclonal T-lymphocyte activation [25] and it triggers
a T-cell mediated neuropathology in vivo [26].
In spite of its pathogenic potential, the exact genomic
origin of MRSV is unknown. When MSRV was discov-
ered, controversy arose regarding whether it was an en-
dogenous or exogenous virus [14]; at present, it seems
that MSRV is most likely transcribed from an HERV-W
endogenous element [27]. The HERV-W family consists
of approximately 650 elements dispersed through thehuman genome [28], but the only member showing a full-
length proviral copy with an ORF is the locus ERVWE1 in
the 7q21.2 chromosome, which encodes Syncytin-1 (Ac-
cession number: AF156963). In silico analyses have re-
vealed that, in addition to the one previously described in
chromosome 7, other putative complete retroviral units of
HERV-W with gag, pro, pol and env might be replication
competent [29]. Among all the HERV-W locations, the
copy in chromosome Xq22.3 (ERVWE2) could be involved
in MSRV expression due to several reasons. First of all,
the env gene at this locus is the only known, besides
ERVWE1, with an ORF only interrupted by a stop codon,
and it has retained its coding capacity producing an al-
most complete N-truncated protein [30] in vitro. This
sequence from chromosome X has important homolo-
gies with several reported MSRV clones derived from
retrotranscription of RNA obtained from retroviral-like
particles in MS patients. For example, the clone pV14
(AF331500) of MSRV env aligned with 98.5% of se-
quence identity and interestingly, the complete clone
CL15 (AF127228) was 99.53% homologous to env + pol
probably reflecting transcription of this region [27].
Moreover, a genetic origin in chromosome X could ex-
plain in part the higher prevalence of MS in women
than in men (2:1 ratio).
In order to find polymorphisms associated with MS
susceptibility that could be related with differential ex-
pression of MSRV in patients and controls, we mapped
the HERV-W insertion in chromosome Xq22.3 and ge-
notyped a total of 1669 patients and 1458 controls, from
two different Spanish cohorts.
Results
Association of MSRV transcription levels with MS
diagnosis and clinical evolution
To confirm the previously published association between
MSRV RNA levels and MS, MSRV RNA expression was
studied by RT-PCR in a randomly selected group of MS
patients (n = 112; 55.6% women) and controls (n = 68;
53.3% women). The analysis was made with a set of
primers and probe able to discriminate between syncytin-1
and MSRV env sequences [31]. MS patients presented
higher MSRV RNA levels compared to controls (U-Mann–
Whitney; p = 0.004) (Figure 1A). Also, we found a correl-
ation with the clinical forms (Spearman’s rho = 0.28;
p = 0.0003) and lower levels of MSRV expression were
found in blood donors (BD) than in relapsing-remitting
(RR) MS patients (U-Mann–Whitney; p = 0.005) or
secondary-progressive (SP) patients (U-Mann–Whitney;
p = 0.005) (Figure 1B).
Regarding clinical parameters, a correlation between
MSRV relative expression and Multiple Sclerosis Sever-
ity Score (MSSS) [32] (Spearman’s rho = 0.25; p = 0.016)
was observed; also the number of relapses suffered in the
Figure 1 Association of MSRV transcription levels with MS diagnosis and clinical evolution. A) MSRV relative expression* was higher in MS
patients (n = 112) compared to controls (n = 68) (U-Mann–Whitney; p = 0.004). B) MSRV relative expression* correlated with clinical forms
(Spearman’s rho; p = 3*10-4). MSRV relative expression* in BD (n = 68) vs. RR patients (n = 81) (U-Mann–Whitney; p = 0.005), RR vs. SP patients
(n = 15) (U-Mann–Whitney; p = 0.108) and BD vs SP patients (U-Mann–Whitney; p = 0.005). C) Correlation of MSRV relative expression* and
MSSS score in women (n = 60) (Spearman’s rho = 0.34; p = 0.017). Subjects were randomly selected. *MSRV Relative Expression = 2e-ΔΔCt = 2e-((Ct
MSRV – Ct GUSB)sample-Mean (Ct MSRV – Ct GUSB)Blood Donors).
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(Spearman’s rho = 0.19; p = 0.06). When we stratified
by sex, the correlation coefficient between the MSRV
expression and MSSS increased in women (Spearman’s
rho = 0.34; p = 0.017) (Figure 1C), while only a trend could
be seen in men (Spearman’s rho = 0.22; p = 0.16).
Mapping of HERV-W copy in chromosome Xq22.3
First, we selected a region of 3 kb (106295193 –
106298196; Human GRCh37, March 2012) including the
complete HERV-W locus. This sequence includes 3′ por-
tions of the pol gene, the complete env gene, and the U3
and R regions of the 3′LTR (Figure 2). Then, we ampli-
fied the sequence through 18 overlapping amplicons.
Each PCR product was analyzed by High Resolution
Melting (HRM) curve analysis in 100 individuals, detect-
ing 5 different mutations: T/C at 445 nt, A/T at 464 nt,
T/C at 1158 nt, G/A at 1943 nt and G/A at 2611 nt from
the beginning of the amplicon. Besides, an insertion of
a G nucleotide was found at 1778 nt. Only 3 of these
variants were detected in more than 5% of the individuals:
T/C at 1158 nt position (SNP1: rs6622139), G/A at
1943 nt (SNP2: rs6622140) and G/A at 2611 nt (SNP3:
rs1290413). The analysis in Haploview 4.0 showed that
rs6622139 and rs6622140 were in perfect linkage disequi-
librium (r2 = 1) and both map in the env open reading
frame; therefore, only rs6622139 and the third polymorph-
ism, rs1290413, were further studied in our cohort.
Association of rs6622139 and rs1290413 with MS
susceptibility
A total of 3127 individuals from two different Spanish
cohorts were genotyped for rs6622139 and rs1290413:
893 MS patients and 664 controls from the discoverycohort (Madrid) and 776 MS patients and 794 controls
from the replication cohort (Andalusia). Clinical and
demographic characteristics of patients and controls are
described in Table 1.
The SNPs were analyzed separately in both sexes due
to their location in chromosome X. Genotyping success
rate was over 98% for both markers. Genotype distribu-
tion of the SNPs in controls and MS patients and p-
values are shown in Table 2.
In the discovery cohort significant associations of
rs6622139 and rs1290413 with MS were found in women.
The homozygous mutant genotype of rs6622139 showed a
protective effect, being more frequent in control than
MS women [p = 0.02; OR (95% CI) =0.44 (0.20 – 0.96)]
and the homozygous mutant genotype of rs1290413
also showed a nominal association with increased predis-
position to MS in women [p = 0.05; OR (95% CI) = 1.81
(0.96-3.47)] (Table 2).
When data of a replication cohort were combined in
order to increase the sample size and gain statistical
power, the association of rs6622139*C in homozygosis
was corroborated [p = 0.004; OR (95% CI) = 0.50 (0.31-
0.81)] (Table 2).
Association of rs6622139 with MS disability
As rs6622139 was associated with MS susceptibility in
women, we analyzed its role in clinical evolution. MSSS
score was available from most patients from the Madrid
cohort, thus the analysis was made including these sub-
jects. Among MS women, carriers of the homozygous mu-
tant genotype for rs6622139 (CC) (n = 9) presented lower
MSSS scores [32] than either CT (n = 118) (U-Mann–
Whitney; p = 0.039) or TT (n = 245) (U-Mann–Whitney;
p = 0.031) carriers (Figure 3).
Figure 2 Position of mapped amplicon in chromosome Xq22.3 (Ensembl Homo Sapiens version 66.37; March 2012) and schematic
location of mutations (M1 and M2), insertion (Ins) and SNPs (rs6622139, rs6622140 and rs1290413), found in HERV-W region.
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In agreement with the susceptibility conferred to women,
rs6622139*T allele was associated with higher levels of
MSRV RNA than rs6622139*C (U-Mann–Whitney;
p = 0.003) in the women with available data analyzed
(Figure 4A). Moreover, a dose-effect was evidenced
from the association of rs6622139 genotypes and
MSRV transcription levels (U-Mann–Whitney; CC vs.
CT: p = 0.033 and CC vs. TT: p = 0.006) (Figure 4B).




Female (n (%)) 593 (66.4)
Age (years) (Mean ± SD) 40.3 ± 9.5
Age at onset (years) (Mean ± SD) 28.6 ± 8.1
Clinical form:
RR (n (%)) 595 (66.6)
SP (n (%)) 51 (5.7)
PP (n (%)) 64 (9)
Disease duration (years) (Mean ± SD) 11 ± 6
Current EDSS score (Mean ± SD) 3 ± 2
*Not available.genotype in this group is very limited, any conclusion
should be taken with caution.
Discussion
In the present study we confirm increased levels of
MSRV transcripts in MS patients compared to controls
and correlation between MSRV expression and clinical
severity (secondary progressive condition and MSSS)
supporting the role of this element in MS pathology. Be-




371 (55.9) 539 (69.5) 513 (64.6)
41.2 ± 16.3 46.1 ± 11.4 40.2 ± 13.8
- 30.8 ± 9.7
- 610 (78.6) -
- 152 (19.6) -
- 60 (7.7) -
- 13.2 ± 9.2 -
n.a*
Table 2 Genotype frequencies and statistical significance for rs6622139 and rs1290413 in Chr.X- HERV-W env copy
rs6622139 (T→ C)
Females
Center of Spain South of Spain
MS Controls p-value OR (95% C.I) MS Controls p-value OR (95% C.I) p MH OR (95% C.I) MH
n % n % n % n %
TT 413 70 245 66 353 65 338 66
TC 167 28 108 29 170 32 148 29
CC 13 2 18 5 0.02* 0.44 (0.20 -0.96) 16 3 27 5 0.06 0.55(0.28-1.08) 0.004** 0.50(0.31-0.81)
Males
Center of Spain South of Spain
MS Controls p-value OR (95% C.I) MS Controls p-value OR (95% C.I) p MH OR (95% C.I) MH
n % n % n % n %
T- 251 84 253 86 0.36 1.23 (0.77-1.99) 194 82 213 76 0.09 0.69(0.44-1.09) ———— ————————
C- 49 16 40 14 43 18 68 24
rs1290413 (G→ A)
Females
Center of Spain South of Spain
MS Controls p-value OR (95% C.I) MS Controls p-value OR (95% C.I) p MH OR (95% C.I) MH
n % n % n % n %
GG 331 56 229 62 296 55 270 53
GA 220 37 127 34 196 36 203 39
AA 42 7 15 4 0.05* 1.81(0.96-3.47) 47 9 40 8 0.59 1.13(0.71-1.79) 0.10 1.34(0.94-1.91)
Males
Center of Spain South of Spain
MS Controls p-value OR (95% C.I) MS Controls p-value OR (95% C.I) p MH OR (95% C.I) MH
n % n % n % n %
G- 219 73 224 76 0.33 1.20(0.81-1.77) 173 73 208 74 0.79 1.05(0.70-1.59) 0.38 0.89(0.68-1.16)
A- 81 27 69 24 64 27 73 26
*Statistically significant difference.
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ism that is associated with MS susceptibility and severity
in women. Finally, we found significant differences be-
tween levels of MSRV expression comparing carriers of
the rs6622139 genotypes. All these findings support the
role of chromosome Xq22.3 HERV-W locus in MSRV
expression and MS etiopathogenesis.
The polymorphism rs6622139 associated with the dis-
ease is in perfect linkage disequilibrium (r2 = 1) with
rs6622140 and both map in the orf of the env sequence.
Taking MSRV env sequence (AF33150) as reference, the
locus ERVWE2 studied here presents a stop codon
at position 39; however, this locus harbours an orf with
a start codon (ATG) at position 68 that encodes for a
N-terminally truncated 475 amino acid Env protein [30].
The N-truncated protein is expressed intracellularly
ex vivo [30], while MSRV env, as a full-length retroviral
envelope protein, is expected to be expressed at the cellsurface. When the stop codon was reverted in vitro the
resulting protein was expressed on the cell surface.
Given the fundamental changes provoked by the elimin-
ation of the stop codon in ERVWE2, it has been specu-
lated that MSRV env sequences could come from
ERVWE2 variants lacking that stop codon [30]. After
mapping ERVWE2 we did not find any mutation revers-
ing the stop codon in our Spanish cohort.
Another hypothesis to explain the origin of the re-
ported MSRV env sequences is that they might derive
from recombination of transcripts from various HERV-
W loci [27]. Apart from the full-length MSRV env, it has
been also suggested that the N-truncated protein
encoded by ERVW2 and other retroviral defective pro-
teins may be expressed in vivo and exert functions in
human physiology or pathology by themselves [30]. In
fact, the primers used here and in other studies [31] that
detect increased levels of HERV-W env (MSRV-type)
Figure 3 Association of rs6622139 with MS disability in women. Carriers of homozygous mutant genotype for rs6622139 (CC) presented
lower MSSS scores than CT (U-Mann–Whitney; p = 0.039) or TT (U-Mann–Whitney; p = 0.031) carriers.
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would detect both the full-length MSRV env and the
N-truncated env sequence encoded by ERVWE2, since
they hybridize at the common C-terminal region. The
SNPs rs6622139 (C/T) and rs6622140 (G/A) map at the
residues 10 and 272, respectively, of the N-truncated
protein (position 38 and 299 from the stop codon) andFigure 4 Association of rs6622139 with MSRV transcription levels in w
was associated to a higher MSRV relative expression* than rs6622139*C alle
according to rs6622139 genotypes (U-Mann–Whitney; CC (n = 3) vs. CT (n =
Expression = 2e-ΔΔCt = 2e-((Ct MSRV – Ct GUSB)sample-Mean (Ct MSRV – Cteither the env protein is full-length or truncated, if
ERVWE2 is involved in its origin, these polymorphisms
would induce variations in its amino-acid sequence:
rs6622139 (T/C) changes glycine by serine and
rs6622140 (G/A) changes threonine by isoleucine. In
both cases the substitution of an amino-acid with a hy-
droxyl (polar) group by an aliphatic one would beomen (MS patients and controls). A) rs6622139*T allele (n = 136)
le (n = 22) (U-Mann–Whitney; p = 0.003). B) MSRV relative expression*
16): p = 0.03 and CC vs. TT (n = 60): p = 0.006). *MSRV Relative
GUSB)Blood Donors).
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ation of the putative protein making epitopes more or
less accessible to the immune cells, and therefore could
alter its antigenic properties. On the other hand, changes
in the nucleotide sequence of the RNA might affect its
stability and thereby influence RNA levels.
The mechanism of generation of MSRV is unknown,
but interestingly, complex interactions between herpes-
viruses, which have been historically studied for their in-
volvement in MS pathogenesis, and HERVs have been
brought to light. In vitro, Epstein-Barr virus (EBV) acti-
vates HERV-W/MSRV/syncytin-1 in cells derived from
blood and brain [33] and antigens from other herpesvi-
ruses as HSV-1, HHV-6, and VZV are able to induce
higher RT activity in peripheral lymphocytes from MS
patients compared to controls [34].
It is well-known that MS is more prevalent in women
than in men. Indeed, the female to male ratio for MS inci-
dence currently ranges from 2:1 to 3:1 and varies by re-
gion [35]. Notably, over the past six decades, this ratio
seems to have increased [36]. Beyond that, gender seems
to influence other aspects of MS as age at onset [37], “par-
ent-of-origin” effect on susceptibility [38] and risk for rela-
tives of MS patients [38]. Although usually women do not
have a poorer prognosis, higher levels of inflammatory le-
sions measured by MRI have been shown in female MS
patients [39] and peripheral immune responses are more
robust in females [40].
The relationship of MSRV with the gender differences
in MS has already been suggested [20]. The DNA copy
number of HERV-W (MSRV-type) is higher in MS pa-
tients than in controls, but it is specially increased in MS
women. Indeed, a possible origin of MSRV in chromo-
some X is supported by the fact that the MSRV proviral
load is higher in females than in men, not only among MS
patients but also among controls [20]. Moreover, MSSS
scores were higher among female patients with an ele-
vated MSRV DNA load [20].
To our knowledge, this is the first demonstration of
the genetic association with MS risk of the HERV-W env
insert in chromosome X. The association supports the
etiopathogenic role of this locus in MS risk, adding on
previously published evidence.
The X chromosome has been proposed to constitute
the common trait of the susceptibility to autoimmune
diseases, other than to explain the female preponderance
of these conditions [41]. A disease-promoting effect
conferred by genes in the X chromosome has been
suggested in females (since some genes escape X inactiva-
tion, resulting in double dosage in females) [41]. The
critical role played by products of single genes located
on the X chromosome or X-linked microRNAs in
autoimmunity is evidenced also by the fact that most
X-linked primary immune deficiencies carry significantautoimmune manifestations [41]. In this sense, the present
data underline the crucial role of loci mapping to chromo-
some X in MS susceptibility.
Conclusions
Our present work reinforces the hypothesis of a direct
involvement of HERV-W/MSRV in MS pathogenesis,
identifying a genetic marker on chromosome X that
might contribute to the gender differences in MS. This
sex-related difference could be exploited to develop
novel therapeutic approaches for MS. Recently, the
safety and pharmacokinetic profiles of GNbAC1, a hu-
manized monoclonal antibody which is directed against
MSRV-Env, have been evaluated and appeared favorable
in healthy male volunteers [42]. In light of the present
results, the next Phase II development program for this
innovative therapeutic approach should include female
patients as well, as an enhanced effect would be ex-
pected in them and would provide a genetic rationale
for the gender bias observed in MS.
Methods
Patients and controls
A total of 1669 patients and 1458 controls from two dif-
ferent regions in Spain were included: from Madrid 893
MS patients (66.4% women) and 664 ethnically and age
matched healthy controls (55.9% women) and from
Andalusia 776 MS patients (69.5% women) and 794 con-
trols (64.6% women); all of them had European ances-
tors. MS diagnosis was established according to
McDonald’s criteria [43]. All individuals participating in
this study signed informed consent and the study was
approved by the Ethics Committees of the respective
hospitals.
None of the control subjects reported any first or sec-
ond degree relatives with any immunological disease.
Clinical and demographic characteristics are enclosed
in Table 1.
Sequence data source
Previously published MSRV-env sequence (GenBank:
AF33150) was used to map the HERV-W env element
located on the negative strand of human chromosome
Xq22.3. This sequence was aligned with the BLAST tool
available at ensemble (http://www.ensembl.org) and en-
larged 1500 nt at both 3′ and 5′ ends.
Primers design
Using PRIMER3 Input version (0.4.0) software (http://
frodo.wi.mit.edu/), a pair of primers specific for the se-
quences adjacent to MSRV in chromosome X as well as
18 pairs of primers to perform High Resolution Melting
curve analysis (HRM) [44] in overlapping amplicons
(Additional file 1: Table S1) were designed.
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The selected amplicon of 3004 bp (106295193 –
106298196; Human GRCh37, March 2012) including
HERV-W locus in chromosome Xq22.3 was amplified by
PCR using the above mentioned specific pair of primers
(Additional file 1: Table S1). PCR reaction was per-
formed on 40 ng of genomic DNA (35 cycles: 94ºC for
30s, 66ºC for 30 s and 68ºC for 180 s) in a final volume
of 10ul of reaction mix containing the primers (0.4 uM),
dNTPs (250uM), MgCl2 (2.5 mM) and 0.8 units of en-
zyme (BIO-X-ACT™ Long polymerase, Bioline). The
amplification of the expected 3Kb fragment was con-
firmed by electrophoresis in 0.8% agarose gel.
High Resolution Melting curve analysis (HRM)
The PCR product of the specific Chr. X region diluted
1/80 on sterile water was used as template to perform
HRM curve analysis on a 7900 Fast Real-Time PCR Sys-
tem (Applied Biosystems), according to manufacturer’s
recommendations. Over 1800 melting curves from 18
different amplicons were analyzed in 100 DNA samples
(50 MS patients and 50 healthy controls).
Sequencing analysis
At least three DNA samples from each group with al-
tered melting curves compared with the average curve
of wild-type subjects were sequenced. When a potential
mutation or single nucleotide polymorphism (SNP) was
detected, samples with the same melting curve were
sequenced with BigDye Cycle sequencing kit (Applied
Biosystems). Before sequencing, each HMR product was
diluted 1/20 on sterile water.
SNPs analysis
The newly described SNPs were analyzed by TaqMan as-
says by design, from Applied Biosystems in an ABI
7900HT Fast Real-Time PCR system (Applied Biosys-
tems), following the manufacturer’s recommendations.
The genotyping success rate was higher than 98%.
MSRV expression analysis
Expression of MSRV was measured by quantitative real
time RT-PCR with the relative method [45] which
needs normalization with a housekeeping (HKG) gene.
Before selecting Glucuronidase-B (GUS-B) as HKG gene,
we analyzed the stability of its expression among MS
patients and controls. The comparison of GUS-B Cts
of both groups did not show significant differences
(ANOVA, p = 0.98). Besides, efficiencies of both assays
(MSRV and GUS-B) were tested by performing standard
curves with serial dilutions of cDNA after retrotran-
scription of total human RNA treated with DNAse
(Applied Biosystems); the efficiencies were 0.92 for
GUS-B assay and 0.98 for MSRV assay.RT positive controls and PCR controls were produced
with the same batch of human total RNA (Applied
Biosystems) as follows: part of the RNA diluted at
10 ng/ul was retrotranscribed into cDNA and then ali-
quoted to be used as “PCR control”; the rest of RNA
was aliquoted to be used as “RT positive control” in each
round of retrotranscription of our study. The cDNA was
tested several times by real time PCR for MSRV and
GUS-B and the means of the Cts were calculated. These
values were used as references for the MSRV and GUS-
B Cts of the “PCR controls” and the “RT positive con-
trols” of each assay, since the same quantity of RNA was
used in both cases. In case of failure, these two controls
allowed us to detect at which step of the RT-PCR the
problem occurred, i.e. if the retrotranscription step did
not work correctly but the PCR did, the Ct of the PCR
control would be similar to the reference value, but the
Ct of the “RT positive control” would differ from them;
on the contrary, if a problem occurred in the PCR step,
both controls would differ from the reference value.
PCR runs were accepted when both controls did not dif-
fer from the reference value more than 2% on Ct basis.
This level of variation was used also to validate the du-
plicates of a sample [46].
From a group of randomly selected MS patients and
blood donors RNA was extracted from PBMCs (Qiamp
RNA Blood Mini kit. Qiagen) obtained by centrifugation
of whole blood on CPT tubes (Becton Dickinson). The
quality and concentration of RNA treated with DNAse
(Applied Biosystems) were assessed by spectrophotom-
eter. Then, sample volumes were adjusted to 10 ng/ul
followed by two-step RT-PCR. Briefly, RNA was retro-
transcribed with the First Strand cDNA Synthesis kit
(Roche Diagnostics) with Oligo dT primers. In each
round of retrotranscription, a positive control consisting
of human total RNA with a known MSRV level of ex-
pression (RT positive control) and a “no RT” control of
each sample, consisting of the same reaction mix with-
out retrotranscriptase, were added. Then, a quantitative
real time PCR was performed on the cDNA with a set of
primers and a specific probe for MSRV [31] and for the
HGK gene GUS-B (Applied Biosystems). Several controls
were included in the PCR runs: 1) “No RT” control of
each sample to detect possible DNA contamination; 2)
RT positive control; 3) PCR control. Thus, the assays for
the detection of GUS-B and MSRV env were considered
acceptable in each sample when: 1) RT positive control
and PCR control did not differ more than 2% on Ct
basis; 2) Ct of HKG was lower than Mean + 2*S.D of
HKG of all samples; 3) no amplification was detected in
the “no RT” control; and 4) the duplicates of each sam-
ple had less than 2% of variability on Ct basis [46].
MSRV relative expression was measured by the 2e-
ΔΔCt relative method [45]: MSRV Relative Expression =
García-Montojo et al. Retrovirology 2014, 11:2 Page 9 of 10
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((Ct MSRV – Ct GUSB)sample-Mean(Ct MSRV – Ct
GUSB)Blood Donors). The mean of the Δ Ct of all the
Blood Donors was used as the calibrator in all the ex-
pression analysis.
Statistical analysis
Statistical analyses were performed using SPSS 15.0.
Linkage disequilibrium values (D’) and Hardy-Weinberg
equilibrium (H-W) were tested with Haploview 4.0
software. Chi-Square test (χ2) was used to compare allele
and genotype frequencies. The Mantel–Haenszel (MH)
test was used to perform the meta-analysis of allele
and genotype frequencies of the two cohorts combined.
MSRV relative expression was not normally distributed,
therefore U-Mann Whitney test was used to compare
MSRV relative expression between two groups. The
non-parametric Spearman test was applied in order
to evaluate the correlation between two variables. Statis-
tically significant differences were considered when
p-value < 0.05.
Additional file
Additional file 1: Table S1. Primers used for mapping HERV-W region
in chromosome Xq22.3.
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